193 related articles for article (PubMed ID: 30931902)
21. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
Colombo MP
Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
[TBL] [Abstract][Full Text] [Related]
22. Cancer Nanomedicine: Lessons for Immuno-Oncology.
Sengupta S
Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932
[TBL] [Abstract][Full Text] [Related]
23. CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
Kranz LM; Beck JD; Grunwitz C; Hotz C; Vormehr M; Diken M
Hum Vaccin Immunother; 2017 Oct; 13(10):2272-2279. PubMed ID: 28846471
[No Abstract] [Full Text] [Related]
24. Immunotherapy in Pediatric Oncology: An Overview of Therapy Types and Nursing Implications.
Warren CB
Clin J Oncol Nurs; 2018 Dec; 22(6):649-655. PubMed ID: 30452014
[TBL] [Abstract][Full Text] [Related]
25. Advances in Cancer Therapy: Immunotherapies.
Marmé D
Oncol Res Treat; 2016; 39(6):324-5. PubMed ID: 27260772
[No Abstract] [Full Text] [Related]
26. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
H Yi D; Appel S
Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
[TBL] [Abstract][Full Text] [Related]
27. [Cancer immunotherapy].
Kjeldsen JW; Donia M; Svane IM
Ugeskr Laeger; 2018 May; 180(21):. PubMed ID: 29804567
[TBL] [Abstract][Full Text] [Related]
28. Macrophages: cancer therapy's double-edged sword.
Brower V
J Natl Cancer Inst; 2012 May; 104(9):649-52. PubMed ID: 22517985
[No Abstract] [Full Text] [Related]
29. Selecting immuno-oncology-based drug combinations - what should we be considering?
Festino L; Vanella V; Trojaniello C; Ascierto PA
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):971-985. PubMed ID: 30169990
[TBL] [Abstract][Full Text] [Related]
30. Cancer Immunotherapy and endocrinology: A new opportunity for multidisciplinary collaboration.
Zafon Llopis C
Endocrinol Diabetes Nutr; 2017 Nov; 64(9):461-463. PubMed ID: 29050701
[No Abstract] [Full Text] [Related]
31. The application of the fibroblast activation protein α-targeted immunotherapy strategy.
Jiang GM; Xu W; Du J; Zhang KS; Zhang QG; Wang XW; Liu ZG; Liu SQ; Xie WY; Liu HF; Liu JS; Wu BP
Oncotarget; 2016 May; 7(22):33472-82. PubMed ID: 26985769
[TBL] [Abstract][Full Text] [Related]
32. Seeking and Exploring Efficient Ways to Target Cancer.
Kallunki T
Cells; 2020 Sep; 9(9):. PubMed ID: 32957725
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind MF; Wagner LM; Cripe TP
Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
[TBL] [Abstract][Full Text] [Related]
34. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
Tong B; Wang M
Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
[TBL] [Abstract][Full Text] [Related]
35. The development of immunotherapy in older adults: New treatments, new toxicities?
Helissey C; Vicier C; Champiat S
J Geriatr Oncol; 2016 Sep; 7(5):325-33. PubMed ID: 27318796
[TBL] [Abstract][Full Text] [Related]
36. Combining cancer vaccines with chemotherapy.
Chong G; Morse MA
Expert Opin Pharmacother; 2005 Dec; 6(16):2813-20. PubMed ID: 16318432
[TBL] [Abstract][Full Text] [Related]
37. [Immunotherapy and targeted therapy, a promising combination to fight cancer].
Andrieu N; Bendriss-Vermare N
Med Sci (Paris); 2018 Oct; 34(10):872-875. PubMed ID: 30451657
[No Abstract] [Full Text] [Related]
38. Immunotherapy-based combinations: an update.
Fucà G; de Braud F; Di Nicola M
Curr Opin Oncol; 2018 Sep; 30(5):345-351. PubMed ID: 29994900
[TBL] [Abstract][Full Text] [Related]
39. Challenges faced when identifying patients for combination immunotherapy.
Ernstoff MS; Gandhi S; Pandey M; Puzanov I; Grivas P; Montero A; Velcheti V; Turk MJ; Diaz-Montero CM; Lewis LD; Morrison C
Future Oncol; 2017 Aug; 13(18):1607-1618. PubMed ID: 28835114
[TBL] [Abstract][Full Text] [Related]
40. The benefits of immunotherapy combinations.
Schmidt C
Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
